(428 days)
"Medi-Cult M3 Medium" is intended for the culture of embryos from day 3 and up to day 7.
"Medi-Cult M3 Medium" is based on MCDB 302; a modification of HAM's F10 and F12 composed of amino acids, vitamins, inorganic salts and glucose supplemented with: Assisted Reproduction Technique Supplement (ARTS) Sodium Bicarbonate Human Serum Albumin (HSA) (obtained from a licensed source, U.S. license No. 140) Penicillin (Except product 1032) Streptomycin (Except product 1032) Phenol Red (Except product 1037)
The provided text describes the 510(k) submission for the "Medi-Cult M3 Medium," a culture medium for human embryos. This document focuses on demonstrating the substantial equivalence of this device to previously marketed predicate devices, rather than presenting a study to prove the device meets specific acceptance criteria in the way an AI/ML device would.
Therefore, many of the requested categories for AI/ML device studies (like expert consensus, standalone performance, MLMC studies, specific sample sizes for training/test sets for an algorithm, etc.) are not applicable to this document as it pertains to a biological culture medium product and not a software algorithm.
However, I can extract information related to the device's performance and the studies mentioned to support its substantial equivalence.
1. Table of Acceptance Criteria and Reported Device Performance
| Acceptance Criteria (Implied) | Reported Device Performance |
|---|---|
| Embryo Viability/Development (Blastocyst Formation Rate) (Implied: Not inferior to predicate devices for extended culture) | Study 1 (Sahlgrenska hospital): Similar rate of blastocyst formation compared to Scandinavian Science S2 medium. |
| Study 2 (Jones Institute): Similar rate of blastocyst formation (26% vs 27% respectively) when compared to a system using S1 and S2 from Scandinavian IVF Science. | |
| Safety (Absence of adverse events/complaints) (Implied: No evidence of serious adverse events or registered complaints) | No registered complaints on the product. No evidence in the last 1.5 year that the product caused serious adverse events in connection with its intended use. |
2. Sample size used for the test set and the data provenance
- Study 1 (Sahlgrenska hospital in Gothenburg, Sweden): Specific sample size not provided. Data provenance: Prospective, randomized study from Sweden.
- Study 2 (Jones Institute for Reproductive Medicine, Norfolk, USA): Specific sample size not provided. Data provenance: Prospective, randomized study from the USA.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts
- Not applicable (N/A). This is a biological culture medium, not an AI/ML device. The "ground truth" here is the biological outcome (blastocyst formation), observed and recorded by clinicians/embryologists, not an interpretation by experts for algorithm validation. Dr. Anita Sjogren (Dept of Ob. & Gyn.) is referenced for data from one study, implying clinical oversight.
4. Adjudication method for the test set
- N/A. As above, this is about biological outcomes, not expert interpretation requiring adjudication. Clinical and embryological protocols would be followed for assessing outcomes.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
- N/A. This is not an AI/ML device.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done
- N/A. This is not an AI/ML device.
7. The type of ground truth used
- Biological Outcomes: The primary "ground truth" or outcome measure for the effectiveness of the culture medium was the rate of blastocyst formation in human embryos. This is a direct biological measure. Safety was assessed by the absence of complaints or serious adverse events.
8. The sample size for the training set
- N/A. This is not an AI/ML device. The term "training set" doesn't apply. The product was used in IVF units in Europe since the late 1980s, providing extensive historical use data, but not a formally defined "training set" for an algorithm.
9. How the ground truth for the training set was established
- N/A. This is not an AI/ML device.
{0}------------------------------------------------
Page 1 of 2
510(k) Summary Summary of Safety and Effectiveness Information Supporting a Substantially Equivalent Determination (K991331)
The products:
- "Medi-Cult M3 Medium" Cat.No. 1033 -
- "Medi-Cult M3 Medium w/o Pen/Strep." Cat.No. 1032 ﮯ
- -"Medi-Cult M3 Medium w/o Phenol Red" Cat.No. 1037
Indication of use:
"Medi-Cult M3 Medium" is intended for the culture of embryos from day 3 and up to day 7.
Product formulation:
"Medi-Cult M3 Medium" is based on MCDB 302; a modification of HAM's F10 and F12 composed of amino acids, vitamins, inorganic salts and glucose supplemented with:
Assisted Reproduction Technique Supplement (ARTS) Sodium Bicarbonate Human Serum Albumin (HSA) (obtained from a licensed source, U.S. license No. 140) Penicillin (Except product 1032) Streptomycin (Except product 1032) Phenol Red (Except product 1037)
Products testing control contents:
- Bioburden, production-test -
- Integrity filter testing, production-test -
- -Sterility, QC-test
- pH, QC-test -
- -Osmolarity, QC-test
- -Endotoxin, OC-test
The culture media from Medi-Cult have been used by many European IVF-units since the end of the 1980's. (Produced and distributed by GEA-Biotech 1987 to 1989 and by Medi-Cult a/s from 1989)
The Medi-Cult M3 medium was introduced in 1992 to allow extended culture of embryos beyond day 2/3 after fertilisation. The Medi-Cult M3 medium has been used by several clinics obtaining good morula/blastocyst formation and good pregnancy rates.
A few prospective randomised studies have been performed showing that the Medi-Cult M3 medium performs equally well as other products available for extended culture.
{1}------------------------------------------------
K991331
Page 2 of 2
One center performed a prospective randomised study comparing the Medi-Cult M3 medium with the Scandinavian Science S2 medium. They found a similar rate of blastocyst formation (Source Dr. Anita Sjogren the Dept of Ob. & Gyn., Sahlgrenska hospital in Gothenburg, Sweden, data presented as poster at The world IVF meeting in Boston 1995).
The Jones Institute for Reproductive Medicine, Eastern Virginia Medical school, Norfolk, USA, has performed a prospective randomised study comparing the rate of blastocyst formation when human embryos are cultured in two different commercially available culture systems. The embryos were cultured either in the Medi-Cult universal IVF-medium for 2 days followed by The Medi-Cult M3 or in S1 for 2 days followed by S2 from Scandinavian IVF Science. The rate of blastocyst formation was similar in both groups (26% vs 27% respectively).
There have been no registered complaints on the product and there is no evidence in the last 1.5 year that the product has been the cause of any serious adverse events in connection with its intended use.
Thus based on the Federal Register Notice (Final Rule, Vol. 63, No. 175, page 48429, September 10, 1998), "Obstetric and Gynecologic Devices; Reclassification and Classification of Medical Devices Used for In-Vitro Fertilization and Related Assisted Reproduction Procedures" effective on October 13, 1998 and the supportive clinical data we feel that the safety and effectiveness of the product for its intended use is shown in the present submission.
Prepared and Submitted by:
Rute Wicheep. Lenardi 1/22/02
Ronald G. Leonardi, Ph. D. Date
Ronald G. Leonardi, Ph. D. President R & R Registrations P.O. Box 262069 San Diego CA 92196 1-858-586-0751
{2}------------------------------------------------
Image /page/2/Picture/1 description: The image shows the logo for the Department of Health & Human Services - USA. The logo features a stylized eagle with three lines representing its body and wings. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the eagle.
Public Health Service
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
JUN 2 0 2000
Medi-Cult A/S c/o Ronald G. Leonardi, Ph.D. President R & R Registrations P.O. Box 262069 San Diego, CA 92196-2069
Re: K991331 Medi-Cult M3 Medium Dated: May 22, 2000 Received: May 23, 2000 Regulatory Class: II 21 CFR §884.6180/Procode: 85 MQL
Dear Dr. Leonardi:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce pror to May 20, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act indude requirements for annual registration, listing of devices, good manufacturing and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalion assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulator, In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notfication submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under Radiation Control provisions, or other Federal laws or regulations.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4591. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html",
Sincerely yours,
Daniel G. Schultz, M.D.
Captain, USPHS Director, Division of Reproductive. Abdominal, and Radiological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure(s)
{3}------------------------------------------------
510(k) Number (if known) K991331
Device Name: Medi-Cult M3 Medium
Indications for Use:
M3 Medium is used for the culture of embryos from day 3 and up to day 7.
(PLEASE DO NO WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use (Per 21 CFR 801.109)
OR
Over-The-Counter Use
(Optional Format 1-2-96)
David A. Ingram
(Division Sign-Off) Division of Reproductive, Abdominal, ENT, and Radiological Devices 510(k) Number
§ 884.6180 Reproductive media and supplements.
(a)
Identification. Reproductive media and supplement are products that are used for assisted reproduction procedures. Media include liquid and powder versions of various substances that come in direct physical contact with human gametes or embryos (including water, acid solutions used to treat gametes or embryos, rinsing solutions, sperm separation media, supplements, or oil used to cover the media) for the purposes of preparation, maintenance, transfer or storage. Supplements are specific reagents added to media to enhance specific properties of the media (e.g., proteins, sera, antibiotics, etc.).(b)
Classification. Class II (special controls) (mouse embryo assay information, endotoxin testing, sterilization validation, design specifications, labeling requirements, biocompatibility testing, and clinical testing). The device, when it is phosphate-buffered saline used for washing, and short-term handling and manipulation of gametes and embryos; culture oil used as an overlay for culture media containing gametes and embryos; and water for assisted reproduction applications, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 884.9.